302 related articles for article (PubMed ID: 33941482)
1. A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.
Kavanagh H; Dunne S; Martin DS; McFadden E; Gallagher L; Schwaber J; Leonard S; O'Dea S
Cytotherapy; 2021 Sep; 23(9):852-860. PubMed ID: 33941482
[TBL] [Abstract][Full Text] [Related]
2. Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing.
VanderBurgh JA; Corso TN; Levy SL; Craighead HG
Sci Rep; 2023 Apr; 13(1):6857. PubMed ID: 37185305
[TBL] [Abstract][Full Text] [Related]
3. Engineering Efficient CAR-T Cells via Electroactive Nanoinjection.
Shokouhi AR; Chen Y; Yoh HZ; Brenker J; Alan T; Murayama T; Suu K; Morikawa Y; Voelcker NH; Elnathan R
Adv Mater; 2023 Nov; 35(44):e2304122. PubMed ID: 37434421
[TBL] [Abstract][Full Text] [Related]
4. Nanoinjection: A Platform for Innovation in Ex Vivo Cell Engineering.
Chen Y; Shokouhi AR; Voelcker NH; Elnathan R
Acc Chem Res; 2024 Jun; 57(12):1722-1735. PubMed ID: 38819691
[TBL] [Abstract][Full Text] [Related]
5. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.
Seki A; Rutz S
J Exp Med; 2018 Mar; 215(3):985-997. PubMed ID: 29436394
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 ribonucleoprotein (RNP) complex enables higher viability of transfected cells in genome editing of acute myeloid cells.
Cheng Q; Xia J; Wang K; Zhang Y; Chen Y; Zhong Q; Wang X; Wu Q
Ann Transl Med; 2022 Aug; 10(16):862. PubMed ID: 36111017
[TBL] [Abstract][Full Text] [Related]
7. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.
Schumann K; Lin S; Boyer E; Simeonov DR; Subramaniam M; Gate RE; Haliburton GE; Ye CJ; Bluestone JA; Doudna JA; Marson A
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10437-42. PubMed ID: 26216948
[TBL] [Abstract][Full Text] [Related]
8. Non-viral chimeric antigen receptor (CAR) T cells going viral.
Balke-Want H; Keerthi V; Cadinanos-Garai A; Fowler C; Gkitsas N; Brown AK; Tunuguntla R; Abou-El-Enein M; Feldman SA
Immunooncol Technol; 2023 Jun; 18():100375. PubMed ID: 37124148
[TBL] [Abstract][Full Text] [Related]
9. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
Billingsley MM; Singh N; Ravikumar P; Zhang R; June CH; Mitchell MJ
Nano Lett; 2020 Mar; 20(3):1578-1589. PubMed ID: 31951421
[TBL] [Abstract][Full Text] [Related]
10. Optimized DNA electroporation for primary human T cell engineering.
Zhang Z; Qiu S; Zhang X; Chen W
BMC Biotechnol; 2018 Jan; 18(1):4. PubMed ID: 29378552
[TBL] [Abstract][Full Text] [Related]
11. Microfluidic and Nanofluidic Intracellular Delivery.
Hur J; Chung AJ
Adv Sci (Weinh); 2021 Aug; 8(15):e2004595. PubMed ID: 34096197
[TBL] [Abstract][Full Text] [Related]
12. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
13. The Past, Present, and Future of Non-Viral CAR T Cells.
Moretti A; Ponzo M; Nicolette CA; Tcherepanova IY; Biondi A; Magnani CF
Front Immunol; 2022; 13():867013. PubMed ID: 35757746
[TBL] [Abstract][Full Text] [Related]
14. High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing.
Lissandrello CA; Santos JA; Hsi P; Welch M; Mott VL; Kim ES; Chesin J; Haroutunian NJ; Stoddard AG; Czarnecki A; Coppeta JR; Freeman DK; Flusberg DA; Balestrini JL; Tandon V
Sci Rep; 2020 Oct; 10(1):18045. PubMed ID: 33093518
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
16. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
17. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
19. Delivering CRISPR: a review of the challenges and approaches.
Lino CA; Harper JC; Carney JP; Timlin JA
Drug Deliv; 2018 Nov; 25(1):1234-1257. PubMed ID: 29801422
[TBL] [Abstract][Full Text] [Related]
20. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
